Histological differentiation predicts post-liver transplantation survival time

被引:11
|
作者
Li, Wen Xia [1 ]
Li, Zhao [1 ]
Gao, Peng Ji [1 ]
Gao, Jie [1 ]
Zhu, Ji Ye [1 ]
机构
[1] Peking Univ, Peoples Hosp, Dept Hepatobiliary Surg, Beijing 01088324175, Peoples R China
关键词
GAMMA-CARBOXY PROTHROMBIN; HEPATOCELLULAR-CARCINOMA; MILAN CRITERIA; UP-TO-7; CRITERIA; TUMOR SIZE; RECURRENCE; EXPERIENCE; RESECTION; CANCER; IMPACT;
D O I
10.1016/j.clinre.2013.11.002
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objectives: Although liver transplantation is the most effective long-term treatment for hepatocellular carcinoma (HCC), the recurrence of HCC remains an issue. Current research examining recurrence after liver transplantation primarily focuses on patients' clinical characteristics. There is no consensus regarding the factors that may relate to predict the survival time and recurrence rates for patients with hepatitis B virus (HBV)-associated HCC transplantation using clinicopathological analysis. Methods: One hundred and three patients with HCC were enrolled in the study. All data were collected from the China Liver Transplant Registry. The independent variables were as follows: age, gender, etiology, preoperative alpha-fetoprotein (AFP) levels, body mass index (BMI), Model for End-stage Liver Disease (MELD) and Child-Pugh scores, primary tumor, regional nodes, metastasis (TNM) classification, number of tumors, the size for the largest tumor, multifocality, portal vein tumor thrombosis and histological differentiation, and prognostic staging score criteria (Milan criteria). All of the patients had previously undergone liver transplantation. Univariate and multivariate analysis were used to determine the factors related to the survival time and recurrence. Results: After a median follow-up period of 41.05 +/- 28.90 months, the 5-year overall survival rate was 46.60%, and the 5-year recurrence rate was 45.63%. Forty-seven patients (45.63%) died due to HCC recurrence during the follow-up period. Patients within Milan criteria exhibited excellent post-transplantation survival times. Univariate analysis suggested that patients with poor tumor differentiation, AFP >= 400 ng/ml, portal vein tumor thrombosis, and TNM staging of I + II had significantly predicted shorter survival times and higher recurrence than patients displaying good or moderate tumor differentiation, AFP < 400 ng/ml, no portal vein thrombosis and TNM staging of III + IV for HBV-associated HCC. However, multivariate analysis revealed that poor tumor differentiation and high serum AFP were associated with a shorter survival time. Moreover, poor tumor differentiation suggested high recurrence. In addition, patients' survival time with AFP < 400 ng/ml was longer than that of patients with AFP >= 400 ng/ml even in patients with HCC beyond Milan criteria. Conclusions: Tumor biological characteristics especially histological differentiation and serum AFP level should be considered before performing liver transplantation (LT) for patients with HBV-associated HCC. Furthermore, the AFP level and histological differentiation provide anew method for assessing HCC patient survival time after LT. Histological differentiation independently predicted post-transplantation survival time and recurrence rate for patients with HBV-associated HCC. (C) 2013 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:201 / 208
页数:8
相关论文
共 50 条
  • [21] Combined proteomic/transcriptomic signature of recurrence post-liver transplantation for hepatocellular carcinoma beyond Milan
    Mamatha Bhat
    Sergi Clotet-Freixas
    Cristina Baciu
    Elisa Pasini
    Ahmed Hammad
    Tommy Ivanics
    Shelby Reid
    Amirhossein Azhie
    Marc Angeli
    Anand Ghanekar
    Sandra Fischer
    Gonzalo Sapisochin
    Ana Konvalinka
    Clinical Proteomics, 2021, 18
  • [22] Combined proteomic/transcriptomic signature of recurrence post-liver transplantation for hepatocellular carcinoma beyond Milan
    Bhat, Mamatha
    Clotet-Freixas, Sergi
    Baciu, Cristina
    Pasini, Elisa
    Hammad, Ahmed
    Ivanics, Tommy
    Reid, Shelby
    Azhie, Amirhossein
    Angeli, Marc
    Ghanekar, Anand
    Fischer, Sandra
    Sapisochin, Gonzalo
    Konvalinka, Ana
    CLINICAL PROTEOMICS, 2021, 18 (01)
  • [23] Lymphocyte-to-Monocyte Ratio Is a Predictor of Survival After Liver Transplantation for Hepatocellular Carcinoma
    Mano, Yohei
    Yoshizumi, Tomoharu
    Yugawa, Kyohei
    Ohira, Masafumi
    Motomura, Takashi
    Toshima, Takeo
    Itoh, Shinji
    Harada, Noboru
    Ikegami, Toru
    Soejima, Yuji
    Maehara, Yoshihiko
    LIVER TRANSPLANTATION, 2018, 24 (11) : 1603 - 1611
  • [24] Intrahepatic Cholangiocarcinoma in the Liver Explant After Liver Transplantation: Histological Differentiation and Prognosis
    Takahashi, Kazuhiro
    Obeid, Joseph
    Burmeister, Charlotte S.
    Bruno, David A.
    Kazimi, Marwan M.
    Yoshida, Atsushi
    Abouljoud, Marwan S.
    Schnickel, Gabriel T.
    ANNALS OF TRANSPLANTATION, 2016, 21 : 208 - 215
  • [25] Follow-up of the Post-Liver Transplantation Patient A Primer for the Practicing Gastroenterologist
    Cheung, Amanda
    Levitsky, Josh
    CLINICS IN LIVER DISEASE, 2017, 21 (04) : 793 - 813
  • [26] Additive impact of pre-liver transplant metabolic factors on survival post-liver transplant
    Adams, Leon A.
    Arauz, Oscar
    Angus, Peter W.
    Sinclair, Marie
    MacDonald, Graeme A.
    Chelvaratnam, Utti
    Wigg, Alan J.
    Yeap, Sze
    Shackel, Nicholas
    Lin, Linda
    Raftopoulos, Spiro
    McCaughan, Geoffrey W.
    Jeffrey, Gary P.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 (05) : 1016 - 1024
  • [27] Evaluation of seven gene signature for predicting HCV recurrence post-liver transplantation
    Salum, Ghada M.
    Abd el Meguid, Mai
    Abelhafez, Tawfeek H.
    Medhat, Eman
    Aziz, Ashraf O. Abdel
    Dawood, Reham
    JOURNAL OF GENETIC ENGINEERING AND BIOTECHNOLOGY, 2021, 19 (01)
  • [28] Biomarker predictors and LRT strategies for HCC recurrence post-liver transplantation: A comment
    He, Tao
    Sun, Ke
    Zou, Jieyu
    JOURNAL OF HEPATOLOGY, 2024, 81 (05) : e242 - e243
  • [29] Hepatopulmonary Syndrome and Post-Liver Transplantation Complications: A Case-Control Study
    Morvan, A.
    Gazon, M.
    Duperret, S.
    Schmitt, Z.
    Pradat, P.
    Mohkam, K.
    Aubrun, F.
    INTERNATIONAL JOURNAL OF ORGAN TRANSPLANTATION MEDICINE, 2020, 11 (04): : 165 - 175
  • [30] The impact of inflammatory bowel disease post-liver transplantation for primary sclerosing cholangitis
    Joshi, Deepak
    Bjarnason, Ingvar
    Belgaumkar, Ajay
    O'Grady, John
    Suddle, Abid
    Heneghan, Michael A.
    Aluvihare, Varuna
    Rela, Mohammed
    Heaton, Nigel
    Agarwal, Kosh
    LIVER INTERNATIONAL, 2013, 33 (01) : 53 - 61